


Lab on a Chip

Miniaturisation for chemistry, physics, biology, materials science and bioengineering

www.rsc.org/loc



ISSN 1473-0197



PAPER

Milica Radisic *et al.*

Microfabricated perfusable cardiac biowire: a platform that mimics native cardiac bundle

Microfabricated perfusable cardiac biowire: a platform that mimics native cardiac bundle†

 Cite this: *Lab Chip*, 2014, 14, 869

 Yun Xiao,^{ac} Boyang Zhang,^{ac} Haijiao Liu,^{bc} Jason W. Miklas,^c Mark Gagliardi,^d Aric Pahnke,^{ac} Nimalan Thavandiran,^{ac} Yu Sun,^{bc} Craig Simmons,^{bc} Gordon Keller^d and Milica Radisic^{*ac}

Tissue engineering enables the generation of three-dimensional (3D) functional cardiac tissue for pre-clinical testing *in vitro*, which is critical for new drug development. However, current tissue engineering methods poorly recapitulate the architecture of oriented cardiac bundles with supporting capillaries. In this study, we designed a microfabricated bioreactor to generate 3D micro-tissues, termed biowires, using both primary neonatal rat cardiomyocytes and human embryonic stem cell (hESC) derived cardiomyocytes. Perfusable cardiac biowires were generated with polytetrafluoroethylene (PTFE) tubing template, and were integrated with electrical field stimulation using carbon rod electrodes. To demonstrate the feasibility of this platform for pharmaceutical testing, nitric oxide (NO) was released from perfused sodium nitroprusside (SNP) solution and diffused through the tubing. The NO treatment slowed down the spontaneous beating of cardiac biowires based on hESC derived cardiomyocytes and degraded the myofibrillar cytoskeleton of the cardiomyocytes within the biowires. The biowires were also integrated with electrical stimulation using carbon rod electrodes to further improve phenotype of cardiomyocytes, as indicated by organized contractile apparatus, higher Young's modulus, and improved electrical properties. This microfabricated platform provides a unique opportunity to assess pharmacological effects on cardiac tissue *in vitro* by perfusion in a cardiac bundle model, which could provide improved physiological relevance.

 Received 3rd October 2013,
Accepted 28th November 2013

DOI: 10.1039/c3lc51123e

www.rsc.org/loc

1. Introduction

Cardiovascular diseases are important targets for pharmacological therapy because they are associated with high morbidity and mortality rates.¹ *In vitro* engineered models may serve as cost-effective alternatives to animal models due to improved system control and higher throughput. In recent years, tissue engineering methods have been significantly advanced to generate functional three-dimensional (3D) cardiac tissues *in vitro*,^{2–4} which better recapitulate the complexity and electro-mechanical function of native myocardium compared to conventional *in vitro* systems of single cell suspensions or monolayers. Moreover, with the opportunities

brought about by human pluripotent stem cells (hPSC), tissue engineering methods hold a great promise in developing patient-specific medical treatment.⁵

In native myocardium, cardiomyocytes are highly anisotropic, usually in a length of 80–100 μm and 20–30 μm in diameter.⁶ Each cardiomyocyte adjoins neighboring cardiomyocytes by specialized intracellular junctions, such as gap junctions and desmosomes, to form a complex 3D network, or syncytium. On tissue level, native cardiomyocytes are organized into spatially well-defined cardiac bundles with supporting vasculature. This highly organized architecture is critical for electro-mechanical activation, propagation of electrical signals, and global cardiac function.⁷ Cardiac tissues generated by current tissue engineering methods often poorly recapitulate this architecture.

Increased cardiovascular risk is one of the major unwanted side effects of new drug candidates, which frequently leads to usage restriction or even withdrawal from the market.⁸ Cardiac toxicity was the main reason behind withdrawal of numerous drugs from the market, including well known examples such as Vioxx or Avandia, accounting for up to 20% of all drug withdrawals.^{9,10} Thus, it is essential to identify these risks at an early stage in drug development process to define safety profile and avoid cost escalation. Despite the exceptional progress in

^a Department of Chemical Engineering and Applied Chemistry, University of Toronto, 164 College St, Rm 407, Toronto, ON, M5S 3G9, Canada.
E-mail: m.radisic@utoronto.ca

^b Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON, Canada

^c Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada

^d McEwen Centre for Regenerative Medicine, University Health Network, Toronto, Ontario, Canada

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c3lc51123e

developing cardiac disease models with hPSC (Timothy,¹¹ long QT,¹² LEOPARD syndrome¹³ and dilated cardiomyopathy patients¹⁴), most studies still use cardiac monolayers that do not capture architectural complexity of the native cardiac niche. After pharmacologic agents are administered into human body, they are circulated through the vasculature and delivered to the myocardium by the blood in capillaries. Current *in vitro* drug testing systems, however, expose the cardiac cells to the pharmacologic agents directly from the culture media in conventional well plates.^{15–18} Thus, developing *in vitro* cardiac systems that can recapitulate the perfusion scenario could provide improved physiological relevance when assessing pharmacological effects on cardiac tissue *in vitro*.

We recently described development of a human cardiac micro-tissue, termed biological wire, which captures some of the architectural complexity of the native myocardium and enables maturation of cardiomyocytes derived from hPSC with the application of electrical stimulation.¹⁹ However, these original biowires lacked perfusion, a critical aspect for mimicking native physiology and mass transfer. We describe here technological developments required to create a perfusable biowire conducive to electrical field stimulation and we prove the feasibility of drug testing in this system.

Perfusable cardiac biowires were generated using a polytetrafluoroethylene (PTFE) tubing template in micro-fabricated bioreactors, which provided contact guidance for cells to align and elongate. To demonstrate the feasibility of this platform for drug testing, we supplied nitric oxide (NO) in the cell culture channel to provide biochemical stimulation to cardiomyocytes within the biowire. NO was released from perfused sodium nitroprusside (SNP) solution and passed through the tubing wall to reach the tissue constructs with cardiomyocytes. This bioreactor was also integrated with electrical stimulation to further improve phenotype of cardiomyocytes.

2. Materials and methods

2.1 Biowire bioreactor design and fabrication

The biowire bioreactor consisted of two main units, the micro-fabricated platform made of poly(dimethylsiloxane) (PDMS) and the suspended template made of either silk 6-0 suture or polytetrafluoroethylene (PTFE) micro-tubing. To fabricate the PDMS platform, standard soft lithography technique was used to make a two-layer SU-8 (Microchem Corp., Newton, MA) master.²⁰ The first layer included the template channel and the cell culture chamber, while the second layer included only the cell culture chamber. Then PDMS was cast onto the SU-8 master and baked for 2 h at 70 °C. A biowire template was then anchored to the two ends of the PDMS platform followed by the bioreactor sterilization in 70% ethanol and overnight UV irradiation.

2.2 Perfusion system design and fabrication

In order to provide perfusion through the tubing template, two microfabricated modules, drug reservoir and connecting

channel, were added to the biowire bioreactor. Both modules were fabricated by first molding PDMS with a single-layer SU-8 master (length × width × height = 10 × 1 × 0.3 mm). The drug reservoir was created by cutting through the PDMS using an 8 mm biopsy punch (Sklar). The biowire bioreactor channel was connected to the drug reservoir and connecting channel with the PTFE tubing (inner diameter (ID) = 0.002 inch, outer diameter (OD) = 0.006 inch, Zeus). Tygon tubing (ID = 0.01 inch, OD = 0.03 inch, Thomas Scientific) connected the perfusion system to external negative pressure generated by a peristaltic pump. The perfusion rate was characterized by the liquid volume collected at the outlet from the peristaltic pump ($n = 3$). All the connecting points were secured by epoxy glue and three microfabricated modules were plasma bonded to a glass slide.

2.3 Cell culture

Neonatal rat cardiomyocytes were obtained from 2 day old neonatal Sprague-Dawley rats as described previously²¹ and according to a protocol approved by the University of Toronto Committee on Animal Care. The culture media contained 10% (v/v) fetal bovine serum, 1% (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), 100 U ml⁻¹ penicillin-streptomycin, 1% Glutamine, and the remainder Dulbecco's modified Eagle's medium.

Cardiac differentiation in embryoid bodies (EBs) of HES-2 human embryonic stem cell (hESC) line was performed as described previously.^{22,23} Briefly, EBs were first cultured in StemPro-34 (Invitrogen) media containing BMP4 (1 ng ml⁻¹). On day 1, they were transferred to the induction medium (StemPro-34, basic fibroblast growth factor (bFGF; 2.5 ng ml⁻¹), activin A (6 ng ml⁻¹) and BMP4 (10 ng ml⁻¹)). On day 4, the EBs were removed from the induction medium and re-cultured in StemPro-34 supplemented with vascular endothelial growth factor (VEGF; 10 ng ml⁻¹) and inhibitor of Wnt production-2 (IWP2; 2 μM). On day 8, the medium was changed again and the EBs were cultured in StemPro-34 containing VEGF (20 ng ml⁻¹) and bFGF (10 ng ml⁻¹) for the remainder of EB culture as well as for the biowire culture. EBs were maintained in hypoxic environment (5% CO₂, 5% O₂) for the first 12 days and then transferred into 5% CO₂ for the remainder of the culture period. EBs were dissociated for seeding in biowires at day 23 (EBd23).

2.4 Generation of cardiac biowires

Cardiac cells (from neonatal rat isolation or hESC differentiation) were first suspended at 200 million ml⁻¹ (unless specified otherwise) in collagen type I based gel (2.5 mg ml⁻¹ of rat tail collagen type I (BD Biosciences) neutralized by 1 N NaOH and 10× M199 media as described by the manufacturer) with the supplements of 4.5 μg ml⁻¹ glucose, 1% HEPES, 10% (v/v) Matrigel (BD Biosciences), and 2 μg ml⁻¹ NaHCO₃. Suspended cardiac cells were then seeded into the cell culture channel (3 μl per biowire). After 30 min incubation at 37 °C to induce the gelation, appropriate media were added. Cardiac biowires

were kept in culture for up to 14 days with media change every 2–3 days.

Cardiac biowires starting with different cell densities (100 and 200 million mL^{-1}) were seeded to study the effect of the cell seeding density. Collagen-based gel was seeded into the cell culture channel without loading cardiac cells, to serve as a cell-free control. Ultra-long cardiac biowires were generated with customized biowire bioreactor that was 5 cm long fabricated in a similar manner as described above and seeded with neonatal rat cardiomyocytes.

2.5 Quantification of compaction rate

After seeding, brightfield images of the biowires were taken every day ($n = 3$ per group) using an optical microscope (Olympus CKX41) and the diameters of the biowires at five distinct locations were averaged with image analysis.

2.6 Immunostaining and fluorescent microscopy

Biowires were fixed with 4% paraformaldehyde, permeabilized by 0.25% Triton X-100, and blocked by 5% bovine serum albumin (BSA). Immunostaining was performed using the following antibodies: mouse anti-cardiac Troponin T (cTnT) (Abcam; 1:100), rabbit anti-Connexin 43 (Cx-43) (Abcam; 1:200), mouse anti- α -actinin (Abcam; 1:200), goat anti-mouse-Alexa Fluor 488 (Jackson Immuno Research; 1:400), anti-rabbit-TRITC (Invitrogen; 1:200), anti-mouse-TRITC (Jackson Immuno Research; 1:200). Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (Biotium; 1:100). Phalloidin-Alexa 660 (Introgen; 1:600) was used to stain F-actin fibers. For confocal microscopy, the stained cardiac biowires were visualized under an inverted confocal microscope (Olympus IX81) or an upright confocal microscope (Zeiss LSM 510).

2.7 Quantification of nuclei elongation and alignment

Cell nuclei within the biowires were visualized by DAPI staining and z-stack images were obtained by confocal microscopy with 3 μm interval. Each stack of the confocal images was analyzed in ImageJ 1.45s (National Institutes of Health, USA) with an automated algorithm described by Xu *et al.*²⁴ with approximately 1000 nuclei analyzed per sample. Nuclei elongations were characterized as nucleus aspect ratios, the ratio of long axis over short axis of the nuclei, and nuclear alignment was characterized by orientation angles. In the control monolayer group, orientation of the nuclei was characterized compared to an arbitrarily defined orientation, while in the biowire group, the orientation of the suture templates was set as reference.

2.8 Characterization of perfusable biowires

Neonatal rat cardiac cells were seeded into the perfusable biowire reactors with tubing template. After cultivation for 7 days, the cardiac biowires were sectioned and visualized

under environmental SEM (Hitachi S-3400N). The biowires were imaged under variable pressure mode at 70 Pa and 15 kV and the chamber temperature was $-20\text{ }^{\circ}\text{C}$.

To visualize the cross-section, perfusable cardiac biowires were stained for cTnT with TRITC conjugated antibody. Stained biowires were then cryo-sectioned into 500 μm thick sections using a cryostat (Leica CM3050S) and mounted to Superfrost Plus glass slide (VWR). Images of the cross-sectioned biowires were acquired by Olympus fluorescent microscope (Olympus IX81).

To demonstrate the feasibility of the perfusable biowire bioreactor, FITC-labeled polystyrene beads (Spherotech Inc.) were added into the drug reservoir and perfused through the rat cardiac biowire, while the biowire beat spontaneously on day 8. Bright-field and fluorescent videos were acquired with a fluorescence microscope (Olympus IX81).

2.9 Quantification of NO perfusion

Sodium nitroprusside (SNP) (Sigma) was dissolved in distilled water to make 200 mM SNP solution and then added to the drug reservoir. Perfusion through the tubing template was driven by the external peristaltic pump. Once the SNP solution perfused through the tubing, the peristaltic pump was stopped and the entire perfusion system was kept in cell culture incubator. NO amount in the cell culture channel (outside the PTFE tubing) was quantified with a fluorometric Nitric Oxide Assay Kit (Calbiochem, 482655). In brief, samples collected from the cell culture channels (8 μL , $n = 3$) at different time points (0.5 h, 6 h, and 24 h) were converted to nitrite by nitrate reductase and then developed into a fluorescent compound 1-*H*-naphthotriazole. The fluorescent signals were quantified by a plate reader (Apollo LB 911, Berthold Technologies) and compared to the nitrate standard.

2.10 NO treatment of human cardiac biowires

On day 7, the NO treatment of human cardiac biowire was initiated by perfusing the 200 mM SNP solution and the peristaltic pump was stopped once the SNP solution was perfused through the tubing. The beating activities of the human cardiac biowires were recorded at 16.67 frames per second before treatment and 24 h post-treatment by Olympus IX81 while the biowires were kept at $37\text{ }^{\circ}\text{C}$. The beating activities of the human cardiac biowires were quantified by the image analysis method described by Sage *et al.*²⁵ In brief, the movements of one spot at the same location on the human cardiac biowire before and after the NO treatment were characterized.

2.11 Electrical stimulation

Different electrical stimulation conditions were applied to the rat cardiac biowires as described previously.² The parallel stimulation chambers were fitted with two 1/4 inch-diameter carbon rods (Ladd Research Industries) placed 2 cm apart, perpendicular to the biowires (such that the electrical field

was parallel with the biowire long axis), and connected to a stimulator (S88X, Grass) with platinum wires (Ladd Research Industries). The perpendicular stimulation chambers were built with two carbon rods 1 cm apart placed parallel with the biowires (*i.e.* the filed was perpendicular to the long axis of the biowire). The biowires were pre-cultured for 4 days until the biowire structures were established and their spontaneous beating was synchronized, and then subjected to the electrical field stimulation (biphasic, rectangular, 1 ms duration, 1.2 Hz, 3.5–4 V cm⁻¹) for 4 days with 10 μM ascorbic acid supplemented in the culture media while control biowires were cultured without electrical stimulation. At the end of electrical stimulation, the rat cardiac biowires were double stained for cTnT with Alexa 488 conjugated antibody and Cx-43 with TRITC conjugated antibody, or their mechanical properties were measured by atomic force microscopy (AFM). Confocal images were acquired using identical microscope settings for all groups. Areas stained positive for cTnT staining (green pixels) or Cx-43 staining (red pixels) were quantified by ImageJ using the identical thresholding parameters in all groups.

For the human perfusable cardiac biowire, only parallel electrical stimulation was applied as described above. Starting on day 4, electrical field stimulations (biphasic, rectangular, 1 ms duration, 1 Hz, 3.5–4 V cm⁻¹) were applied for 4 days while control biowires were cultured without electrical stimulation. Both stimulated and control biowires were perfused with culture medium at a flow rate of 2 μl min⁻¹ within the PTFE tubing driven by an external syringe pump (PHD Ultra; Harvard Apparatus). At the end of electrical stimulation, the electrical properties of the stimulated and control human cardiac biowires were characterized in terms of excitation threshold (ET) and maximum capture rate (MCR) under external field pacing as previously described.²⁶

2.12 Atomic force microscopy (AFM)

After application of electrical stimulations for 4 days, rat cardiac biowires were tested using a commercial AFM (Bioscope Catalyst; Bruker) mounted on an inverted optical microscope (Nikon Eclipse-Ti). The force-indentation measurements were done with a spherical tip (radius = 5–10 μm) at nine distinct spots to evenly cover the center of the cardiac biowires with 5 nN trigger force at 1 Hz indentation rate. The cantilever (MLCT-D, Bruker) had a nominal spring constant of 0.03 N m⁻¹. Hertz model was applied to the force curves to estimate the Young's modulus and detailed data analysis was described elsewhere.²⁷ All AFM measurements were done in fluid environment at room temperature.

2.13 Statistical analysis

Statistical analysis was performed using SigmaPlot 11.0. Differences between experimental groups were analyzed using *t*-test or one-way ANOVA with significant difference considered as *p* < 0.05.

3. Results

3.1 Generation and characterization of cardiac biowires

The native myocardium has a highly anisotropic structure (Fig. 1a) with a high density of capillaries (Fig. 1b) and surrounding elongated and aligned cells (Fig. 1c). In the native heart, extracellular matrix (ECM) serves as a template for cells to align and elongate.²⁸ In addition, a structural correlation between directionality of capillaries and cardiomyocytes can be readily observed.⁶ We aimed to emulate this in our biowire bioreactor by introducing a perfusable tubing template and by using a hydrogel, for cell seeding, consisting of ECM molecules normally present in the native heart. Primary neonatal rat cardiomyocytes were used to generate 3D, self-assembled cardiac biowires by seeding within type I collagen-based gel into microfabricated PDMS platforms with suspended templates (Fig. 2b). Seeded cells remodeled and contracted the collagen gel matrix around the templates within a week (Fig. 2a, 4a). The gel compaction only occurred with the presence of the seeded cells, as cell-free gels did not compact or degrade during the culture time, and the compaction rate positively correlated with the cell seeding density (Fig. 2d). Cardiac biowires of different dimensions could be generated by customizing the dimensions of the biowire bioreactor. Here, we generated biowires as long as 5 cm (Fig. 2c). Generation of longer biowires might be possible; however it was not explored in this work.

Image analysis of the cell nuclei that counterstained with DAPI (Fig. 3a, left) revealed nuclei elongation and alignment along the axis of suture template. There was a significant difference (*p* < 0.001) of nuclei aspect ratio between biowires and monolayer group (Fig. 3b). Compared to neonatal rat cardiomyocytes cultured in monolayer controls, biowires had a lower frequency of cells in the smaller aspect ratio range and a higher frequency of cells in the larger aspect ratio range (Fig. 3c). Image analysis also revealed that cell nuclei in biowires were oriented along with the axis of the suture template, while those in monolayers were randomly distributed (Fig. 3d).

Neonatal rat cardiac biowires started to beat spontaneously between 3 and 4 days post-seeding and kept beating during gel compaction, demonstrating that the biowire bioreactor allowed for electromechanical coupling of the cells within the hydrogel matrix. The spontaneous beating of biowires with higher seeding density (200 million ml⁻¹) started earlier and was more prominent than in those with lower seeding density (100 million ml⁻¹) (Video 1†), which is thought to be a result of the presence of more cardiomyocytes and better coupling. Immunohistochemistry staining showed that the rat cardiac biowires expressed the sarcomeric protein, cTnT (Fig. 3a, right).

3.2 Generation and characterization of perfusable cardiac biowires

Primary neonatal rat and hESC-derived cardiomyocytes were used to generate perfusable cardiac biowires with PTFE tubing template (Fig. 4d). Both cell types were able to form the cardiac




Fig. 1 Cardiac bundles in native myocardium. (a) Schematic illustration of the structure of cardiac bundles in native myocardium. Cardiomyocytes are elongated, aligned, and grouped into bundles around capillaries. (b) Tangential section of adult rat myocardium with CD31 staining (brown). Nuclei were counterstained as light violet (long arrows). The blood vessels were noted as asterisks while the capillaries were noted as short arrows. (c) Fluorescent image of tangential cryosection of neonatal rat myocardium. Cardiac troponin T (cTnT) was stained against Alexa 488-labeled (green) antibody, showing its unique striation structure. Cell nuclei were counterstained with DAPI (blue) and the long arrows indicate elongated nuclei.

biowires and beat spontaneously (Fig. 4a, Videos 2, 3, and 4†). As shown in SEM images, cells attached to the smooth surface of the PTFE tubing after self-remodeling (Fig. 4b). Cross sections of these perfusable biowires showed that self-remodeled cells encircled the tubing template and expressed cTnT (Fig. 4c).

The feasibility of perfusable biowire bioreactor was demonstrated by perfusion with FITC-labeled fluorescent beads. Perfusion rate driven by the peristaltic pump was quantified to be $2 \pm 0.16 \mu\text{l min}^{-1}$ ($n = 3$). Bright field video showed both spontaneous beating activity of the rat cardiac biowire and the perfusion of the fluorescent beads (Video 2†). The movement of the beads was better visualized under fluorescent view. A snapshot of the video (Fig. 4e) was overexposed to provide better visualization of the fluorescent beads. The cardiac biowire was also visible in this image due to the autofluorescence of cardiomyocytes.

3.3 NO treatment of human cardiac biowires by perfusion

To demonstrate feasibility of drug testing in the perfusable cardiac biowire, a pharmacological agent, NO donor SNP,

was perfused through the tubing lumen. As NO was generated in the tubing lumen, it diffused through the tubing wall reaching the cell culture outer channel where the total amount of NO was quantified. The amount of NO released from 200 mM SNP was quantified by a fluorometric assay which validated the persistence of the NO release from SNP solution over several hours (Fig. 5a). The cumulative NO amount in the cell culture channel was $100 \mu\text{M}$ (800 pmol in $8 \mu\text{l}$), which exceeded the physiological levels of NO *in vivo*.²⁹

Upon gel compaction, the hESC-derived cardiomyocytes within the biowires started spontaneous beating (Videos 3 and 4†). After NO treatment for 24 h, performed by perfusion of NO donor SNP through the tubing lumen, the spontaneous beating of human cardiac biowires slowed down (Video 5†) and this was further characterized by image analysis (Fig. 5b, c). In order to compare beating frequency changes between different biowires, the frequencies after 24 h NO treatment were normalized to the basal level (before treatment). The beating frequencies after NO treatment were significantly lower than the basal level ($74 \pm 3\%$, $n = 3$) while the control biowires remained the same ($100 \pm 9\%$, $n = 3$).




Fig. 2 Generation of cardiac biowires in a microfabricated bioreactor. (a) Within 7 days of cultivation, neonatal rat cardiomyocytes ($8.75 \text{ million cells ml}^{-1}$) remodeled the gel and compacted around the suture template to form the biowire structure. (b) Device design of the microfabricated bioreactor with suspended 6-0 suture template. (c) A customized ultra-long cardiac biowire in the length of 5 cm (scale bar = $500 \mu\text{m}$). (d) Quantification of gel compaction and its dependence on initial seeding density of cardiomyocytes (mean \pm SD, $n = 3$). With no cardiomyocytes seeded (gel only), the gel did not compact and form biowire structure. Biowires with higher seeding density ($200 \text{ million cells ml}^{-1}$) compacted faster than those with lower seeding density ($100 \text{ million cells ml}^{-1}$) during the remodelling.

The degradation of cytoskeleton of cardiomyocytes within the biowires based on hESC derived cardiomyocytes caused by NO treatment through perfusion was characterized using confocal microscopy for α -actinin labeled with Alexa 488 conjugated antibody (green) and actin labeled with Alexa 660 conjugated antibody (far red) (Fig. 5d). It was possible to clearly discern the striated pattern of sarcomeric Z-discs

labeled with α -actinin in the control biowires, while the NO treated biowires showed an overall punctate pattern.

3.4 Electrical stimulation of cardiac biowires

To demonstrate the versatility of the cardiac biowire bioreactor, electrical stimulation was applied to further improve




Fig. 3 The suture template provides topographical cues in the biowires for the cardiomyocytes to elongate and align. (a) Confocal images of the biowire with nuclei counterstained with DAPI and cardiac Troponin-T (cTnT) stained with Alexa 488 conjugated antibody (green). (b) Nuclei aspect ratios (~1000 nuclei characterized per sample) of cardiac cells cultured as a monolayer vs. seeded in the biowires plotted in box plot showing the 1st quartile, median, and 3rd quartile with a significant difference between two groups (***, $p < 0.001$). (c) Histogram showing the distribution of nuclei aspect ratios of biowire group and monolayer group ($n = 3$ per group). There were significantly higher frequencies in the lower aspect ratio range in the monolayer group (*, $p < 0.05$) and higher frequencies in higher aspect ratio range in the biowire group (#, $p < 0.05$). (d) Characterization of nucleus orientation reveals random distribution of nuclei in the monolayer group (random direction as 0°) and oriented distribution of nuclei along with the suture template in the biowire group (orientation of suture template as 0°). Dashed lines indicate orientation angle, solid hemi-circular lines indicate the percentage gridlines, and grey (monolayer) or blue (biowire) lines indicate the actual percentage of the nuclei in the specific orientation angle.




Fig. 4 Generation of perfusable cardiac biowires. (a) Neonatal rat cardiomyocytes ($200 \text{ million cells ml}^{-1}$) remodeled the gel and compacted around the tubing template (ID = $50.8 \mu\text{m}$, OD = $152.4 \mu\text{m}$). A close-up view showing the tubing lumen at the end of the biowire is given at top-right. (b) SEM images demonstrate that the cardiac tissue attached to the tubing surface and formed a uniform-thick layer after remodelling. (c) Representative phase contrast image (left) and confocal image (right) showing the circular morphology of the cross section of the perfusable cardiac biowire with expression of cardiac Troponin-T (cTnT). (d) Set-up of the perfusion device. Two microfabricated modules were added to the bioreactor system: a drug reservoir at one end of the biowire and a channel at the other end for connection to an external negative pressure source. The entire biowire perfusion system was bonded on a glass slide (real-life image shown at the top-left corner). (e) The tubing-templated biowire was perfused with FITC-labeled polystyrene beads ($1 \mu\text{m}$ in diameter). Solid lines illustrate the wall of the cell culture channel. FITC-labeled beads were indicated by arrows. Asterisks indicate the auto fluorescence from the cardiomyocytes within the cardiac biowire. This image was over-exposed to better visualize the fluorescent beads.




Fig. 5 Nitric oxide (NO) treatment on human tubing-templated biowires. (a) Quantification of NO amount passing through the tubing wall after perfusing SNP (200 mM) for 0.5 h, 6 h, and 24 h. (b) 24 h NO treatment significantly slowed down the beating of biowires compared to the basal levels while there was no significant change in the non-treated biowires ($n = 3$ per group, $p < 0.01$). (c) Quantified by image analysis, the beating rate of a biowire after 24 h NO treatment was less frequent compared to the basal level. (d) Confocal images showing the disrupted α -actinin (green) structure within the NO-treated biowire (right) compared to the control (left) (top: lower magnification; bottom: higher magnification).




Fig. 6 Electrical stimulation and perfusion of cardiac biowires. (a) Experimental set-up of biowires under different electrical stimulation conditions. Carbon rods (in black) connected to an external stimulator provided either parallel or perpendicular electrical field stimulation on cardiac biowires for 4 days starting on day 4. (b) Representative confocal images of biowires after application of different electrical stimulation conditions (left: lower magnification; right: higher magnification). Parallel-stimulated biowires showed more cTnT positive (green) structures oriented along with the suture template (indicated by dashed lines). (c) Higher ratio of Cx-43 positive area over cTnT positive area indicated stronger expression of Cx-43 in both parallel- and perpendicular-stimulated biowires compared to the non-stimulated controls ($n = 4$ per group, $p < 0.05$). (d) Young's modulus of cardiac biowires characterized by AFM reveals that the parallel-stimulated biowires had improved mechanical properties compared to the control biowires (**, $p < 0.01$). (e) Electrically stimulated perfused biowires based on hESC derived cardiomyocytes had lower excitation threshold compared to the non-stimulated controls (***, $p < 0.001$). (f) The electrically stimulated perfused biowires based on hESC derived cardiomyocytes had higher maximum capture rate compared to the non-stimulated controls (*, $p < 0.05$).

the phenotype of cardiomyocytes (Fig. 6a). Immunohistochemical staining showed that the rat cardiomyocytes in the biowires that underwent electrical stimulation with the field parallel to the biowire long axis had more cTnT positive structures oriented along with the axis of the suture template (indicated by the dashed line), while those in non-stimulated biowires were randomly distributed and those in perpendicular-stimulated biowires were found to be perpendicular to the suture template (Fig. 6b). Moreover, the cardiomyocytes in the parallel- and perpendicular-stimulated biowires showed stronger expression of Cx-43, a marker for the gap junctions between adjacent cardiomyocytes, compared to the control biowires, indicating better coupling between the cardiomyocytes in the stimulated groups (Fig. 6b). This was also confirmed by comparing the ratio of Cx-43 positive area over cTnT positive area under same magnification with identical microscope settings (Fig. 6c).

When handling the rat cardiac biowires outside the bioreactor, it was noticed that the parallel-stimulated biowires were stiffer than the non-stimulated control. This was further assessed by AFM analysis ($n = 3$ per group), which revealed significantly ($p = 0.009$) improved mechanical properties of parallel-stimulated biowires compared to non-stimulated controls (Fig. 6d).

The perfusable human cardiac biowires that underwent medium perfusion through the tubing and parallel electrical stimulation at the same time showed improved electrical properties compared to the non-stimulated controls as assessed by ET and MCR under electrical field stimulation. The ET is the minimum electrical field voltage required for inducing synchronous contractions and the decreased ET of the stimulated biowires (Fig. 6e) indicated better electrical excitability. The MCR is the maximum beating frequency attainable while maintaining synchronous contractions and the increased MCR (Fig. 6f) of the stimulated biowires indicated improved cell alignment and interconnectivity.

4. Discussion

The native myocardium consists of spatially well-defined cardiac bundles with supporting vasculature (Fig. 1a) and the cardiomyocytes within the cardiac bundles are highly anisotropic (Fig. 1b). In this study, we have developed a microfabricated bioreactor to generate cardiac biowires *in vitro* recapitulating the structure and function of native cardiac bundles. To the best of our knowledge, this is the first study to examine the drug effects on cardiomyocytes by perfusion in a cardiac bundle model, which better mimics native myocardium mass transfer properties compared to other engineered heart tissues. This bioreactor provided topographical cues for the cardiac cells to elongate and align, and was also integrated with other cues, *e.g.* electrical stimulation.

Gel compaction has been widely applied in tissue engineering to create 3D microtissue constructs for *in vivo* implantation³⁰ and *in vitro* models.^{16,31} Compared to scaffold-based constructs, the self-assembled constructs from

gel compaction produce increased force of contraction due to the higher cell density after the compaction.³² Moreover, there is increasing interest in microtissue constructs made by gel compaction as microarrays for drug testing because they provide much higher throughput than conventional models.^{16,31,33,34} In this study, type I collagen was chosen as the main gel matrix as it is one of the main ECM components of native myocardium. We noted that previous *in vitro* collagen-based models only stayed intact for several days due to their poor mechanical properties.³¹ In our microfabricated system, with the mechanical support provided by the suspended templates, the cardiac biowires remained stable in the bioreactor for weeks. We were able to generate cardiac tissues in larger scale (up to 5 cm long) compared to other *in vitro* models and the dimensions of the cell culture channel could be easily customized, which could render additional control over the morphology of the cardiac biowires. The cell culture channels were initially designed to be 300 μm in height considering the limitations for oxygen and nutrient supply.³⁵ Moreover, the presence of the templates enabled easy disassembly of the biowire from the bioreactor and facile handling of the cardiac biowires at the end of cultivation for further characterization.

The feasibility of handling individual cardiac biowire together with the ability to create macro-scale biowires raise up the prospect of investigating the alignment of multiple cardiac biowires by bundling or weaving them together to generate thicker structures, using similar methods as described by Onoe *et al.*³⁶ To characterize the force generated by the cardiac biowires or cardiac biowire bundles, degradable sutures could be used to generate template-free cardiac biowires which will be a topic of our future studies.

To validate our microfabricated bioreactor, neonatal rat cardiomyocytes were used in preliminary studies. Only when seeded at higher cell density ($>5 \times 10^7$ cells mL^{-1}), which is comparable to the cell density in the native rat myocardium ($\sim 10^8$ cells mL^{-1}),³⁷ the cardiac biowires started spontaneous beating on day 3–4. The template provided contact guidance for the cells to elongate and align along with, recapitulating the anisotropic properties of cardiomyocytes in the native myocardium. The image analysis was done on cell nuclei due to the difficulty of defining cell membranes within 3D tissue. However, nuclear alignment is a sufficient indication of cell alignment and also one of the hallmarks of native myocardium (Fig. 1c).

To further develop the biowire system, we used PTFE tubing as the template instead of the 6-0 silk suture. The commercially available PTFE tubing was chosen because it is biocompatible (USP Class VI), extremely non-absorbent (ideal for drug testing), and micro-scale in dimension (ID = 50 μm , OD = 150 μm), on the order of post-capillary venules in size.³⁸ Due to the small size of the inner lumen, we used negative pressure to drive the perfusion instead of positive pressure. Two microfabricated modules were added to the system to enable long-term perfusion and incubation

of the biowire system. Indicated by the shortening of biowire during self-remodeling, the cell attachment on PTFE tubing was not as strong as that on silk suture, mainly because of the smoothness of the PTFE tubing surface (Fig. 4b). However, the cell-gel composite was still able to assemble itself around the tubing with a circular cross-section (Fig. 4c).

In this study, NO was chosen as a model drug because of following reasons: (1) NO is produced by endothelial cells in native myocardium, and then transported in the radial direction to cardiomyocytes,³⁹ the scenario we were trying to recapitulate in our biowire bioreactor; (2) NO plays a critical role in regulating myocardial function, through both vascular-dependent and -independent effects;³⁹ (3) there is increasing evidence showing that NO is directly implicated in cardiomyocyte disease development and prevention, such as in ischemia-reperfusion injury;⁴⁰ (4) NO is a small gas molecular, which can readily pass the tubing wall. SNP was chosen as the NO donor because it is a common NO donor used in clinical studies.^{41,42} Moreover, SNP aqueous solution was reported to release NO at a constant rate over several hours *in vitro*.⁴³

For the NO treatment testing, we generated human cardiac biowires from hESC-derived cardiomyocytes. The human cardiac biowire started spontaneous beating as early as day 1 and the beating was synchronized within 7 days. After 24 h of NO treatment, the beating frequencies of the human cardiac biowires significantly slowed down compared to their basal level. This result corresponds with the vasodilator effect of NO *in vivo*⁴⁴ and might be caused by degradation of myofibrillar cytoskeleton, which has been seen by Chiusa *et al.*⁴⁵ However, NO shows bi-polar inotropic effect at lower concentrations with diverse intracellular mechanisms and there were discrepancies between studies due to the lack of standardization for *in vitro* models.³⁹ Therefore our microfabricated bioreactor could serve as a novel platform to uncover the effects of NO on cardiomyocytes at the tissue level.

To demonstrate the versatility of our biowire bioreactors, electrical stimulation was integrated with the system as it has been reported to improve the phenotypes of cardiomyocytes.^{2,20} Because the cells in the cardiac biowires were anisotropic, we studied both parallel- and perpendicular-field electrical stimulations on the rat biowires. The higher tissue stiffness under parallel electrical stimulation, which was closer to isolated neonatal rat cardiac tissue (6.8 ± 2.8 kPa),⁴⁶ were attributed to more organized cellular contractile apparatus as characterized by immunohistochemical staining. The perfusable human cardiac biowires were electrically stimulated and perfused at the same time and this brings the prospect to study the interaction between electrical stimulation and pharmaceutical agents delivered in a physiological manner. A more detailed study on electrical stimulation alone of biowires based on human pluripotent cardiomyocytes has been done in our group and indicated that electrical stimulation of progressive frequency increase markedly improved the maturation of hPSC-derived

cardiomyocytes in terms of myofibril structure and electrical properties.¹⁹

Medium perfusion has been recognized to improve the viability and functionality of cardiomyocytes within cardiac constructs *in vitro* since perfusion significantly improves oxygen and nutrient supply.⁴⁷ In most of previous studies, bioreactors provided medium perfusion by sandwiching cell-laden porous scaffold, while exposing the cardiomyocytes directly to the flow.^{47–49} This does not exactly recapitulate the native myocardium where the blood supply flows through a dense vascular network that minimizes transport distances but also protects cardiomyocytes from shear.⁵⁰ More recently, bioreactors were developed to provide the electrical stimulation and medium perfusion simultaneously and it was shown that perfusion and stimulation had a synergistic effect on improving the contractile functionality of the cardiac constructs.^{51,50} However, the cardiac constructs in these systems were based on porous scaffolds and therefore unable to provide the information about the effect of electrical stimulation on anisotropic cardiac tissue.

Previous studies describe the design of perfusion bioreactors that enable high-throughput *in vitro* drug testing on cardiac constructs.^{52,49} Kaneko *et al.* designed a microchamber array chip to evaluate single cell level interactions for drug testing.⁵² Agarwal *et al.* designed a bioreactor composed of a microarray of cantilevers that was able to characterize diastolic and systolic stresses generated by anisotropic cardiac microtissue in real-time and the bioreactor could provide electrical stimulation on these cardiac microtissues.⁴⁹ These two studies characterized cardiac function on either single cell or monolayer level, which might be insufficient to provide accurate information of cardiac disease as in our complex native system. Moreover, the drugs investigated in these studies were directly applied to the cells, instead of the blood compartment, and the presence of flow generated shear stress on cardiomyocytes, both of which contributed to the generation of an unphysiological environment compared to that cardiomyocytes experience in the native heart.

There are several advantages of our microfabricated cardiac biowire bioreactors: (1) they are a better mimic of the native cardiac bundle structure with anisotropic alignment; (2) the presence of the template enables easier handling for later characterization and keeps the entire structure stable for weeks; (3) the device could be easily customized and applicable for high-throughput drug screening; (4) the platform provides topographical stimulation by itself; (5) the platform is versatile and could be integrated with other stimuli as well (*e.g.* mechanical stimulation); (6) the perfusable cardiac biowire system is the first platform to study pharmacological agents applied to cardiomyocytes by perfusion through cardiac bundle mimic and could provide valuable knowledge on cardiac disease development and therapeutics.

While this perfusable cardiac biowire platform provides us many opportunities, there are still some limitations of our current platform. The permeability of the commercially available PTFE tubing renders limitation on the drug candidates

that can be tested, as only small molecules can diffuse appreciably through the tubing wall and proteins cannot. Ideal tubing materials should be microporous for better permeability. Further studies are required to investigate other relevant pharmacological agents and seeding endothelial cells in the tubing lumen to study the interaction between endothelial cells and cardiomyocytes could also be pursued.

5. Conclusions

In conclusion, we have developed a microfabricated cardiac biowire bioreactor that is capable of testing pharmacological agents applied by perfusion through the lumen. The bioreactor provides topographical cues for the cardiomyocytes to assemble and align. Moreover, it could be integrated with other stimuli to further improve the phenotypes of the cardiomyocytes. The engineered cardiac biowires could serve as *in vitro* models that recapitulate the structure and function of the *in vivo* cardiac bundles for studies of cardiac development and disease.

Acknowledgements

The authors would like to thank Zheng Gong for his kind help with preparing Fig. 3d. This work was funded by grants from Ontario Research Fund–Global Leadership Round 2 (ORF-GL2), Natural Sciences and Engineering Research Council of Canada (NSERC) Strategic Grant (STPGP 381002-09), Canadian Institutes of Health Research (CIHR) Operating Grant (MOP-126027), NSERC-CIHR Collaborative Health Research, Grant (CHRPJ 385981-10), NSERC Discovery Grant (RGPIN 326982-10), NSERC Discovery Accelerator Supplement (RGPAS 396125-10), National Institutes of Health grant 2R01 HL076485 and Heart and Stroke Foundation grant (T6946).

References

- 1 A. S. Go, D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, S. Dai, E. S. Ford, C. S. Fox, S. Franco, H. J. Fullerton, C. Gillespie, S. M. Hailpern, J. A. Heit, V. J. Howard, M. D. Huffman, B. M. Kissela, S. J. Kittner, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, D. Magid, G. M. Marcus, A. Marelli, D. B. Matchar, D. K. McGuire, E. R. Mohler, C. S. Moy, M. E. Mussolino, G. Nichol, N. P. Paynter, P. J. Schreiner, P. D. Sorlie, J. Stein, T. N. Turan, S. S. Virani, N. D. Wong, D. Woo and M. B. Turner, *Circulation*, 2013, **127**, e6–e245.
- 2 M. Radisic, H. Park, H. Shing, T. Consi, F. J. Schoen, R. Langer, L. E. Freed and G. Vunjak-Novakovic, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 18129–18134.
- 3 W. H. Zimmermann, K. Schneiderbanger, P. Schubert, M. Didie, F. Munzel, J. F. Heubach, S. Kostin, W. L. Neuhuber and T. Eschenhagen, *Circ. Res.*, 2002, **90**, 223–230.
- 4 T. Shimizu, M. Yamato, Y. Isoi, T. Akutsu, T. Setomaru, K. Abe, A. Kikuchi, M. Umezumi and T. Okano, *Circ. Res.*, 2002, **90**, e40–e48.
- 5 D. Sinnecker, A. Goedel, K.-L. Laugwitz and A. Moretti, *Circ. Res.*, 2013, **112**, 961–968.
- 6 S. Y. Ho, *Eur. J. Echocardiogr.*, 2009, **10**, iii3–iii7.
- 7 P. J. Hunter, A. J. Pullan and B. H. Smaill, *Annu. Rev. Biomed. Eng.*, 2003, **5**, 147–177.
- 8 B. Fermini and A. A. Fossa, *Nat. Rev. Drug Discovery*, 2003, **2**, 439–447.
- 9 U.S. Food and Drug Administration, *Recalls, Mark. Withdrawals Saf. Alerts*, 2012.
- 10 J. P. Piccini, D. J. Whellan, B. R. Berridge, J. K. Finkle, S. D. Pettit, N. Stockbridge, J.-P. Valentin, H. M. Vargas and M. W. Krucoff, *Am. Heart J.*, 2009, **158**, 317–326.
- 11 M. Yazawa, B. Hsueh, X. Jia, A. M. Pasca, J. A. Bernstein, J. Hallmayer and R. E. Dolmetsch, *Nature*, 2011, **471**, 230–234.
- 12 A. Moretti, M. Bellin, A. Welling, C. B. Jung, J. T. Lam, L. Bott-Flügel, T. Dorn, A. Goedel, C. Höhnke, F. Hofmann, M. Seyfarth, D. Sinnecker, A. Schömig and K.-L. Laugwitz, *N. Engl. J. Med.*, 2010, **363**, 1397–1409.
- 13 X. Carvajal-Vergara, A. Sevilla, S. L. D'Souza, Y.-S. Ang, C. Schaniell, D.-F. Lee, L. Yang, A. D. Kaplan, E. D. Adler, R. Rozov, Y. Ge, N. Cohen, L. J. Edelmann, B. Chang, A. Waghay, J. Su, S. Pardo, K. D. Lichtenbelt, M. Tartaglia, B. D. Gelb and I. R. Lemischka, *Nature*, 2010, **465**, 808–812.
- 14 N. Sun, M. Yazawa, J. Liu, L. Han, V. Sanchez-Freire, O. J. Abilez, E. G. Navarrete, S. Hu, L. Wang, A. Lee, A. Pavlovic, S. Lin, R. Chen, R. J. Hajjar, M. P. Snyder, R. E. Dolmetsch, M. J. Butte, E. A. Ashley, M. T. Longaker, R. C. Robbins and J. C. Wu, *Sci. Transl. Med.*, 2012, **4**, 130ra47.
- 15 K. Shapira-Schweitzer, M. Habib, L. Gepstein and D. Seliktar, *J. Mol. Cell. Cardiol.*, 2009, **46**, 213–224.
- 16 A. Hansen, A. Eder, M. Bönstrup, M. Flato, M. Mewe, S. Schaaf, B. Aksehirlioglu, A. P. Schwoerer, A. Schwörer, J. Uebeler and T. Eschenhagen, *Circ. Res.*, 2010, **107**, 35–44.
- 17 E. Serena, E. Cimetta, S. Zatti, T. Zaglia, M. Zagallo, G. Keller and N. Elvassore, *PLoS One*, 2012, **7**, e48483.
- 18 N. Christoforou, B. Liau, S. Chakraborty, M. Chellapan, N. Bursac and K. W. Leong, *PLoS One*, 2013, **8**, e65963.
- 19 S. S. Nunes, J. W. Miklas, J. Liu, R. Aschar-Sobbi, Y. Xiao, B. Zhang, J. Jiang, S. Massé, M. Gagliardi, A. Hsieh, N. Thavandiran, M. A. Laflamme, K. Nanthakumar, G. J. Gross, P. H. Backx, G. Keller and M. Radisic, *Nat. Methods*, 2013, **10**, 781–787.
- 20 H. T. Heidi Au, B. Cui, Z. E. Chu, T. Veres and M. Radisic, *Lab Chip*, 2009, **9**, 564–575.
- 21 L. A. Reis, L. L. Y. Chiu, Y. Liang, K. Hyunh, A. Momen and M. Radisic, *Acta Biomater.*, 2012, **8**, 1022–1036.
- 22 L. Yang, M. H. Soonpaa, E. D. Adler, T. K. Roepke, S. J. Kattman, M. Kennedy, E. Henckaerts, K. Bonham, G. W. Abbott, R. M. Linden, L. J. Field and G. M. Keller, *Nature*, 2008, **453**, 524–528.
- 23 S. J. Kattman, A. D. Witty, M. Gagliardi, N. C. Dubois, M. Niapour, A. Hotta, J. Ellis and G. Keller, *Cell Stem Cell*, 2011, **8**, 228–240.

- 24 F. Xu, T. Beyazoglu, E. Hefner, U. A. Gurkan and U. Demirci, *Tissue Eng., Part C*, 2011, **17**, 641–649.
- 25 D. Sage, F. R. Neumann, F. Hediger, S. M. Gasser and M. Unser, *IEEE Trans. Image Process.*, 2005, **14**, 1372–1383.
- 26 L. L. Chiu, R. K. Iyer, J. P. King and M. Radisic, *Tissue Eng., Part A*, 2011, **17**, 1465–1477.
- 27 H. Liu, Y. Sun and C. A. Simmons, *J. Biomech.*, 2013, **46**, 1967–1971.
- 28 D.-H. Kim, E. A. Lipke, P. Kim, R. Cheong, S. Thompson, M. Delannoy, K.-Y. Suh, L. Tung and A. Levchenko, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 565–570.
- 29 C. N. Hall and J. Garthwaite, *Nitric Oxide*, 2009, **21**, 92–103.
- 30 W.-H. Zimmermann, I. Melnychenko, G. Wasmeier, M. Didie, H. Naito, U. Nixdorff, A. Hess, L. Budinsky, K. Brune, B. Michaelis, S. Dhein, A. Schwoerer, H. Ehmke and T. Eschenhagen, *Nat. Med.*, 2006, **12**, 452–458.
- 31 W. R. Legant, A. Pathak, M. T. Yang, V. S. Deshpande, R. M. McMeeking and C. S. Chen, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 10097–10102.
- 32 K. Baar, R. Birla, M. O. Boluyt, G. H. Borschel, E. M. Arruda and R. G. Dennis, *FASEB J.*, 2005, **19**, 275–277.
- 33 G. Kensah, I. Gruh, J. Viering, H. Schumann, J. Dahlmann, H. Meyer, D. Skvorc, A. Bär, P. Akhyari, A. Heisterkamp, A. Haverich and U. Martin, *Tissue Eng., Part C*, 2011, **17**, 463–473.
- 34 T. Boudou, W. R. Legant, A. Mu, M. A. Borochin, N. Thavandiran, M. Radisic, P. W. Zandstra, J. A. Epstein, K. B. Margulies and C. S. Chen, *Tissue Eng., Part A*, 2012, **18**, 910–919.
- 35 M. Radisic, J. Malda, E. Epping, W. Geng, R. Langer and G. Vunjak-Novakovic, *Biotechnol. Bioeng.*, 2006, **93**, 332–343.
- 36 H. Onoe, T. Okitsu, A. Itou, M. Kato-Negishi, R. Gojo, D. Kiriya, K. Sato, S. Miura, S. Iwanaga, K. Kuribayashi-Shigetomi, Y. T. Matsunaga, Y. Shimoyama and S. Takeuchi, *Nat. Mater.*, 2013, **12**, 584–590.
- 37 M. Radisic, M. Euloth, L. Yang, R. Langer, L. E. Freed and G. Vunjak-Novakovic, *Biotechnol. Bioeng.*, 2003, **82**, 403–414.
- 38 M. P. Wiedeman, *Circ. Res.*, 1963, **12**, 375–378.
- 39 P. B. Massion, O. Feron, C. Dessy and J.-L. Balligand, *Circ. Res.*, 2003, **93**, 388–398.
- 40 E. T. Chouchani, C. Methner, S. M. Nadtochiy, A. Logan, V. R. Pell, S. Ding, A. M. James, H. M. Cochemé, J. Reinhold, K. S. Lilley, L. Partridge, I. M. Fearnley, A. J. Robinson, R. C. Hartley, R. A. J. Smith, T. Krieg, P. S. Brookes and M. P. Murphy, *Nat. Med.*, 2013, **19**, 753–759.
- 41 R. R. Miller, L. A. Vismara, R. Zelis, E. A. Amsterdam and D. T. Mason, *Circulation*, 1975, **51**, 328–336.
- 42 W. Mullens, Z. Abrahams, G. S. Francis, H. N. Skouri, R. C. Starling, J. B. Young, D. O. Taylor and W. H. W. Tang, *J. Am. Coll. Cardiol.*, 2008, **52**, 200–207.
- 43 L. Ederli, L. Reale, L. Madeo, F. Ferranti, C. Gehring, M. Fornaciari, B. Romano and S. Pasqualini, *Plant Physiol. Biochem.*, 2009, **47**, 42–48.
- 44 M. Seddon, A. M. Shah and B. Casadei, *Cardiovasc. Res.*, 2007, **75**, 315–326.
- 45 M. Chiusa, F. Timolati, J. C. Perriard, T. M. Suter and C. Zuppinger, *Eur. J. Histochem.*, 2012, **56**, e15.
- 46 B. Bhana, R. K. Iyer, W. L. K. Chen, R. Zhao, K. L. Sider, M. Likhitpanichkul, C. A. Simmons and M. Radisic, *Biotechnol. Bioeng.*, 2010, **105**, 1148–1160.
- 47 M. Radisic, H. Park, F. Chen, J. E. Salazar-Lazzaro, Y. Wang, R. Dennis, R. Langer, L. E. Freed and G. Vunjak-Novakovic, *Tissue Eng.*, 2006, **12**, 2077–2091.
- 48 M. Radisic, L. Yang, J. Boublik, R. J. Cohen, R. Langer, L. E. Freed and G. Vunjak-Novakovic, *Am. J. Physiol.*, 2004, **286**, H507–H516.
- 49 A. Agarwal, J. A. Goss, A. Cho, M. L. McCain and K. K. Parker, *Lab Chip*, 2013, **13**, 3599–3608.
- 50 R. Maidhof, N. Tandon, E. J. Lee, J. Luo, Y. Duan, K. Yeager, E. Konofagou and G. Vunjak-Novakovic, *J. Tissue Eng. Regener. Med.*, 2012, **6**, e12–e23.
- 51 Y. Barash, T. Dvir, P. Tandeitnik, E. Ruvinov, H. Guterman and S. Cohen, *Tissue Eng., Part C*, 2010, **16**, 1417–1426.
- 52 T. Kaneko, K. Kojima and K. Yasuda, *Analyst*, 2007, **132**, 892–898.